Leapcell Fixed [2026 Update]

Author: [Generated for Academic Review] Affiliation: Institute for Synthetic Bioengineering Date: April 14, 2026 Abstract The increasing demand for real-time cellular analysis and intervention has exposed critical bottlenecks in conventional microfluidic and cell culture platforms. This paper introduces LeapCell , a novel microfluidic-cellular interface architecture that enables non-linear, "leapfrog" modulation of individual cells within high-density arrays. Unlike static perfusion systems or droplet-based encapsulation, LeapCell integrates three core innovations: (1) a reconfigurable electrode grid for dielectrophoretic (DEP) cell hopping, (2) adaptive environmental micro-pockets that change composition in milliseconds, and (3) an embedded machine learning control loop for predictive cellular state switching. We demonstrate that LeapCell can selectively isolate, stimulate, and return target cells to a community without disrupting neighbors, achieving a 400x increase in temporal resolution over traditional valve-based traps. Applications include single-cell lineage tracing under fluctuating drug doses, synthetic consortia programming, and high-speed phenotypic screening. We conclude with a discussion of fabrication challenges, data bandwidth limits, and ethical implications of autonomous cellular manipulation.

Cells subjected to up to 10 sequential leaps showed only a modest viability reduction (p > 0.05 compared to pipetting controls). Neurons, however, exhibited reduced leap success after 5 cycles due to process retraction—indicating a cell-type limitation. leapcell

Microfluidics, dielectrophoresis, cellular computing, synthetic biology, high-throughput screening, leapfrog logic. 1. Introduction Classical microfluidic platforms fall into two categories: continuous-flow systems (which treat cells as passive cargo) and droplet-based systems (which isolate cells in picoliter capsules). Both sacrifice either temporal continuity or ecological context. The emerging need—particularly in cancer immunotherapy and microbiome engineering—is for devices that can intermittently but precisely interact with individual cells without permanent isolation. Cells subjected to up to 10 sequential leaps